EXPRESSION AND FUNCTIONAL-ROLE OF C-KIT LIGAND (SCF) IN HUMAN MULTIPLE-MYELOMA CELLS

被引:46
作者
LEMOLI, RM
FORTUNA, A
GRANDE, A
GAMBERI, B
BONSI, L
FOGLI, M
AMABILE, M
CAVO, M
FERRARI, S
TURA, S
机构
[1] UNIV BOLOGNA,INST HAEMATOL,BOLOGNA,ITALY
[2] UNIV BOLOGNA,INST HISTOL & EMBRYOL,BOLOGNA,ITALY
[3] UNIV MODENA,INST BIOL CHEM,I-41100 MODENA,ITALY
[4] UNIV MODENA,EXPTL HAEMATOL LAB,I-41100 MODENA,ITALY
关键词
SCF; MULTIPLE MYELOMA; GENE EXPRESSION; CELL PROLIFERATION; AUTOCRINE-PARACRINE GROWTH LOOP;
D O I
10.1111/j.1365-2141.1994.tb05115.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In this study we investigated the proliferation of three well-documented MM lines and 10 bone marrow samples from myeloma patients in response to rh-SCF alone and combined with Interleukin-6 (IL-6), IL-3 and IL-3/GM-CSF fusion protein PIXY 321. Neoplastic plasma cells were highly purified (>90%) by immunomagnetic depletion of T, myeloid, monocytoid and NK cells. The number of S-phase cells was evaluated after 3 and 7 d of liquid culture by the bromodeoxyuridine (BRDU) incorporation assay. The proliferation of RPMI 8226 and U266 cell lines was also assessed by a clonogenic assay. AU the experiments were performed in serum-free conditions. RPMI 8226 cell line was not stimulated by SCF which also did not augment the proliferative activity of IL-6, IL-3 and PIXY-321. Conversely, SCF addition resulted in 2.4-fold increase of the number of U266 colonies and in a higher number of U266 and MT3 cells in S-phase (24.5 +/- 2% SEM v 14.5 +/- 1% SEM and 32 +/- 3% SEM v 21 +/- 4% SEM, respectively; P < 0.05). The c-kit ligand also enhanced the proliferation of MT3 and U266 cells mediated by the other cytokines. Anti-SCF polyclonal antibodies completely abrogated the proliferative response of MT3 cells to exogenous SCF and markedly reduced the spontaneous growth of the same cell line. Reverse transcriptase-polymerase chain reaction amplification (RT-PCR) did detect SCF mRNA in MT3 and RPMI 8226 cells. Moreover, secreted SCF was found, in a biologically active form, in the supernatant of the two cell lines by the MO7e proliferation assay. When tested on fresh myeloma samples, SCF increased the number of S-phase plasma cells (4.7 +/- 1.6% v 3.4 +/- 1.3% in control cultures; P = 0.02). Significant proliferation was also induced by IL-6 (7 +/- 2.3% of BRDU(+) cells; P = 0.006), IL-3 (5.3 +/- 1.3%; P = 0.01) and PIXY-321 (5.4 +/- 1.6%; P = 0.02). The addition of SCF significantly enhanced the proliferation of myeloma cells responsive to IL-6. In summary, our results indicate that SCF is expressed in MM cells and stimulates the proliferation of neoplastic plasma cells.
引用
收藏
页码:760 / 769
页数:10
相关论文
共 40 条
[1]  
ANDERSON KC, 1989, BLOOD, V73, P1915
[2]  
BARLOGIE B, 1989, BLOOD, V73, P865
[3]   SERUM LEVELS OF INTERLEUKIN-6, A POTENT MYELOMA CELL-GROWTH FACTOR, AS A REFLECT OF DISEASE SEVERITY IN PLASMA-CELL DYSCRASIAS [J].
BATAILLE, R ;
JOURDAN, M ;
ZHANG, XG ;
KLEIN, B .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (06) :2008-2011
[4]  
BERENSON J, 1987, BLOOD, V70, P1550
[5]   INTERLEUKIN-3 AND INTERLEUKIN-6 SYNERGISTICALLY PROMOTE THE PROLIFERATION AND DIFFERENTIATION OF MALIGNANT PLASMA-CELL PRECURSORS IN MULTIPLE-MYELOMA [J].
BERGUI, L ;
SCHENA, M ;
GAIDANO, G ;
RIVA, M ;
CALIGARISCAPPIO, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (02) :613-618
[6]  
BILLIPS LG, 1992, BLOOD, V79, P1185
[7]  
BONSI L, 1993, STEM CELLS, V11, P131
[8]  
BROXMEYER HE, 1991, BLOOD, V77, P2142
[9]  
CALIGARISCAPPIO F, 1991, BLOOD, V77, P2688
[10]   INVITRO GROWTH OF HUMAN MULTIPLE-MYELOMA - IMPLICATIONS FOR BIOLOGY AND THERAPY [J].
CALIGARISCAPPIO, F ;
GREGORETTI, MG ;
GHIA, P ;
BERGUI, L .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1992, 6 (02) :257-271